Lived experience of older adults with type 1 diabetes using closed‐loop automated insulin delivery in a randomised trial
Authors' conclusion
The lived experience of older adults without frailty or major cognitive impairment using first-generation closed-loop therapy was mainly positive and concordant with glycaemic benefits found in the trial. Older adults' lived experience using automated insulin delivery beyond trial environments requires exploration; moreover, the usability needs of older adults should be considered during future device development.
Study context
- Population
- Adults aged ≥60 years with long-duration T1D who used first-generation closed-loop therapy (MiniMed 670G) in a crossover trial vs sensor-augmented pump therapy20 functionally independent
- Participants
- 21 adults
- Outcome
- Lived experience of closed-loop therapy
Methodological detailssemi-structured interviews, thematic analysis, nested in randomised, open-label, two-stage crossover trial
- Semi-structured interviews
- Thematic analysis
- Nested in randomised, open-label, two-stage crossover trial
Main finding
As reported in the abstract
- QoL benefits, incl. improved sleep and reduced diabetes-related psychological burden, with improved glucose levels
- Gaps between expectations and reality, with disappointment amongst some participants
- Cost perceived as a barrier to continued closed-loop access post-trial
- Usability issues, e.g. disruptive overnight alarms and sensor inaccuracy
Original publication
Lived experience of older adults with type 1 diabetes using closed‐loop automated insulin delivery in a randomised trial. Diabet Med. Published 15 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →